• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Successful prophylaxis using activated prothrombin complex concentrates (aPCC) in a severe haemophilia A patient with inhibitor previously unresponsive to on-demand daily infusions of aPCC.

作者信息

Furukawa S, Nogami K, Ogiwara K, Yada K, Shima M

机构信息

Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan.

出版信息

Haemophilia. 2017 Sep;23(5):e481-e484. doi: 10.1111/hae.13310. Epub 2017 Aug 3.

DOI:10.1111/hae.13310
PMID:28771891
Abstract
摘要

相似文献

1
Successful prophylaxis using activated prothrombin complex concentrates (aPCC) in a severe haemophilia A patient with inhibitor previously unresponsive to on-demand daily infusions of aPCC.
Haemophilia. 2017 Sep;23(5):e481-e484. doi: 10.1111/hae.13310. Epub 2017 Aug 3.
2
Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain.在西班牙，有抑制剂的重度血友病 A 患者中，使用活化的凝血酶原复合物浓缩物进行预防治疗与按需使用活化因子 VII 治疗的成本分析。
Haemophilia. 2015 May;21(3):320-329. doi: 10.1111/hae.12681. Epub 2015 Apr 9.
3
Tissue factor pathway inhibitor in activated prothrombin complex concentrates (aPCC) moderates the effectiveness of therapy in some severe hemophilia A patients with inhibitor.活化凝血酶原复合物浓缩物（aPCC）中的组织因子途径抑制剂会降低某些患有抑制剂的严重甲型血友病患者的治疗效果。
Int J Hematol. 2014;99(5):577-87. doi: 10.1007/s12185-014-1572-4. Epub 2014 Apr 1.
4
A decade-long clinical experience on the prophylactic use of activated prothrombin complex concentrate in acquired haemophilia A: a case series from a tertiary care centre.关于活化凝血酶原复合物浓缩物在获得性血友病A预防性使用中的十年临床经验：来自三级医疗中心的病例系列
Blood Coagul Fibrinolysis. 2018 Apr;29(3):282-287. doi: 10.1097/MBC.0000000000000716.
5
Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain.在西班牙，重组活化因子 VII 与血浆源性活化凝血酶原复合物浓缩物治疗重型血友病 A 伴抑制物患者轻至中度出血发作的成本效益比较。
Haemophilia. 2013 Nov;19(6):841-6. doi: 10.1111/hae.12199. Epub 2013 Jun 11.
6
Cost effectiveness of prophylactic treatment with activated prothrombin complex concentrate in a patient with inhibitor-positive hemophilia A.在一名抑制物阳性的甲型血友病患者中使用活化凝血酶原复合物浓缩物进行预防性治疗的成本效益。
Blood Coagul Fibrinolysis. 2012 Apr;23(3):235-7. doi: 10.1097/MBC.0b013e32834fb582.
7
Activated prothrombin complex concentrate (FEIBA®) for the treatment and prevention of bleeding in patients with acquired haemophilia: A sequential study.活化凝血酶原复合物浓缩剂（FEIBA®）用于获得性血友病患者出血的治疗和预防：一项序贯研究。
Thromb Res. 2015 Dec;136(6):1299-302. doi: 10.1016/j.thromres.2015.10.032. Epub 2015 Oct 22.
8
Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction.血友病抑制物患者出血的预防：新出现的数据和临床方向。
Am J Hematol. 2004 Oct;77(2):187-93. doi: 10.1002/ajh.20162.
9
Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.评估抑制物血友病患者使用 FEIBA 预防的获益。
Haemophilia. 2010 Mar;16(2):263-71. doi: 10.1111/j.1365-2516.2009.02126.x. Epub 2009 Dec 16.
10
Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A--a two-centre experience.联合使用抗凝血酶原复合物（FEIBA®）和氨甲环酸治疗伴抑制物的血友病 A 患者和获得性血友病 A 患者——一项两中心经验。
Haemophilia. 2012 Jul;18(4):544-9. doi: 10.1111/j.1365-2516.2012.02748.x. Epub 2012 Feb 20.